AI Article Synopsis
- Advanced cutaneous squamous cell carcinoma (cSCC) represents only 5% of cases but is responsible for 60% of related deaths, highlighting its severity.
- Historically, treatment options have been limited, facing challenges like low effectiveness and high side effects.
- The approval of a new treatment by the US FDA in 2018 marks a significant improvement for patients, and the article reviews past and present treatments while looking ahead to future advancements.
Article Abstract
Advanced cutaneous squamous cell carcinoma (cSCC) accounts for only 5% of all cases of cSCC but up to 60% of disease related deaths. Historically, this disease has lacked effective treatment options due to a combination of poor response rate, poor response durability and significant treatment-associated morbidity. Autumn of 2018 marked the first time ever that an agent received US FDA approval for advanced cSCC and the future is looking much brighter for this previously neglected patient population. The purpose of this article is to review the various systemic treatment options for advanced cSCC moving from the past to the present, highlighting their relative merits and shortcomings, and to briefly speculate on future developments in the field of advanced cSCC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/fon-2019-0158 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!